Skip to main content

Table 5 Routine laboratory parameters: mean difference and standard deviation (SD) between treatment group (aVQ) and control group by independent t -test and result of the repeated measured analysis of variance (ANOVA, influence of treatment)

From: Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma – a randomized, controlled pilot study

 

Values at baseline (SD)

Difference between aVQ and control

 

aVQ

Control

t

t

t

t

F

   

at baseline

at week 8

at week 16

at week 24

ANOVA

WBCx1000/μl

6.21 (2.13)

5.24 (1.17)

−1.595

−2.1951*

−2.0243

−2.1076*

7.614*

Platelets x1000/μl

61.38 (77.07)

72.19 (83.77)

0.38

−0.5491

0.2193

0.3207

0.0442

Neutrophils %

64.65 (8)

63.66 (8.29)

−0.345

−0.7475

1.6094

−0.291

0.0055

Lymphocytes %

21.83 (6.37)

22.94 (7.51)

0.4493

2.1109*

−0.068

1.0294

1.5019

Monocytes %

7.07 (2.91)

7.74 (3.69)

0.5746

0.5052

0.2823

0.8871

0.776

Eosinophils %

6.08 (3.89)

4.91 (2.39)

−1.028

−3.677**

−3.2466**

−2.3029*

10.1286**

Basophiles %

0.37 (0.21)

0.76 (0.63)

2.3308*

0.4129

0.0282

−0.081

2.0996

Protein g/dl

6.16 (0.44)

6.31 (0.37)

1.0894

0.1437

0.3964

1.0308

0.4806

AST U/l+

19.62 (4.26)

21 (8.48)

0.5798

0.4339

1.0689

0.4566

0.6618

ALT U/l

19.44 (9.39)

20.31 (11.27)

0.2386

0.064

1.3147

−0.0086

0.2651

ALK U/l‡

65.75 (16.43)

72.56 (48.02)

0.5369

−2.146*

−3.0221**

−2.8479**

2.6545

Bilirubin mg/dl

0.84 (0.24)

0.79 (0.28)

−0.471

−0.1546

−0.4448

−0.6975

0.2735

  1. +AST: aspartate aminotransferase; ALT: alanine aminotransferase; ‡ ALK: alkaline phosphatase; *p<0.05 **p<0.01.